Navigation Links
New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women

CLEVELAND--(BUSINESS WIRE)--May 10, 2007 - An evaluation of the safety and effectiveness of local vaginal estrogen therapy for the treatment of vaginal atrophy, a frequent complaint of postmenopausal women, has just been released by The North American Menopause Society (NAMS). Entitled "The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society," the document was developed by an Editorial Board of five clinicians and researchers expert in this area of women's health, then approved by the NAMS Board of Trustees.

"Although hot flashes typically accompany the loss of ovarian estrogen production at menopause, they usually abate over time regardless of whether estrogen therapy is used," said Gloria A. Bachmann, MD, Associate Dean for Women's Health, Professor of Obstetrics and Gynecology and Professor of Medicine, UMDNJ, Robert Wood Johnson Medical School, New Brunswick, NJ, and Chair of the Editorial Board. "In contrast, vaginal symptoms (eg, vaginal dryness, vulvovaginal irritation and itching, and painful intercourse) are usually progressive and unlikely to resolve spontaneously. Left untreated, vaginal atrophy can result in years of discomfort, with a significant impact on quality of life. An estimated 10% to 40% of postmenopausal women have symptoms related to vaginal atrophy, yet only about 25% of symptomatic women seek medical help."

The new position statement represents the most authoritative state-of-the-science summary. Significant findings include:

-- Estrogen therapy, used either locally (ie, vaginally) or systemically (eg, orally, through the skin), is considered the therapeutic standard for moderate to severe vaginal atrophy.

-- Local vaginal delivery of estrogen is available in North America in government-approved therapies via cream, tablet, and ring--with fewer systemic effects than estrogen by topical, parenteral, or oral delivery.

-- Randomized controlled trials, although limited, have shown that low-dose, local vaginal estrogen delivery is effective and well tolerated for treating vaginal atrophy.

-- All the low-dose vaginal estrogen products approved in the United States for treatment of vaginal atrophy are equally effective at the doses recommended in labeling. Choice of therapy should be guided by clinical experience and patient preference.

-- Progestogen is generally not indicated when low-dose estrogen is used locally for vaginal atrophy.

-- Data are insignificant to recommend annual surveillance of the endometrium (lining of uterus) in asymptomatic women using vaginal estrogen.

-- Vaginal estrogen therapy should be continued for as long as symptoms that are distressing to the patient remain.

-- For women treated for non-hormone-dependent cancer, management of vaginal atrophy is similar to that for women without a cancer history.

-- For women with a history of hormone-dependent cancer, management recommendations are dependent upon each woman's preference in consultation with her oncologist.

The position statement is published in the May/June 2007 issue of the Society's official journal, Menopause. It has been designated a NAMS CME activity (print/online). A PDF of the paper, as well as a set of nine slides that summarize the paper's contents, are available without charge from the NAMS Web site (

NAMS is grateful to Novo Nordisk, Inc., for its educational grant that supported development of this statement.

The Mission of NAMS, a nonprofit scientific organization, is to promote the health and quality of life of women through an understanding of menopause. The Society's membership of 2,000 professionals representing a variety of disciplines--including clinical and basic science experts from medicine, nursing, pharmacy, a nthropology, sociology, psychology, and complementary/alternative medicine--makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause. (


McKinney Advertising & Public Relations
Judy Cerne, 216-621-5133
President & CEO
Fax: 216-621-1181
The North American Menopause Society
Pamela P. Boggs, MBA, 440-442-7658
Director of Education & Development
Fax: 440-442-2660


Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Obama Statement on Bush Veto of Stem Cell Bill
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
5. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
6. Northfield Laboratories Investor Update
7. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
8. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... On November 10, 2015, Bohrer Brady, LLC filed a ... behalf of a home health care worker who provided companionship services for the elderly, ... workers employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published November ... more widely heralded as a breakthrough for performing hernia repairs. The article explains that ... surgery is that it can greatly reduce the pain that a patient might otherwise ...
(Date:11/25/2015)... OH (PRWEB) , ... November 25, 2015 , ... Dental ... implants in Cleveland, OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant ... this year in Cleveland, OH. , As the co-founders of Advanced Implant Mentoring ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... athletic programs, launches new Wimbledon Athletics Facebook page to educate the ... for unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy Products, ... personal heating products business. Cozy Products explains what this means for business moving forward. ... with the Cozy Products business model: to sell personal heaters that reduce energy consumption, ...
Breaking Medicine News(10 mins):